Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study

BACKGROUND: Clinical significance of various subtypes of epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) remains unclear. METHODS: We analyzed EGFR ex19del subtypes in NSCLC patients receiving first‐line tyrosine kinase inhibitor (TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Yangchun, Yu, Jinyu, Hu, Haifeng, Zhang, Hua, Cao, Baoshan, Liang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626247/
https://www.ncbi.nlm.nih.gov/pubmed/37704565
http://dx.doi.org/10.1111/1759-7714.15108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626247/
https://www.ncbi.nlm.nih.gov/pubmed/37704565
http://dx.doi.org/10.1111/1759-7714.15108

Ejemplares similares